Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd

SZSE:002864 주식 보고서

시가총액: CN¥3.0b

Shaanxi Panlong Pharmaceutical Group Limited By Share 미래 성장

Future 기준 확인 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Shaanxi Panlong Pharmaceutical Group Limited By Share.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Pharmaceuticals 수익 성장19.3%
매출 성장률n/a
향후 자기자본 수익률n/a
애널리스트 커버리지

None

마지막 업데이트n/a

최근 미래 성장 업데이트

업데이트 없음

Recent updates

There Is A Reason Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd's (SZSE:002864) Price Is Undemanding

Sep 30
There Is A Reason Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd's (SZSE:002864) Price Is Undemanding

Shaanxi Panlong Pharmaceutical Group Limited By Share's (SZSE:002864) Shareholders Will Receive A Bigger Dividend Than Last Year

May 31
Shaanxi Panlong Pharmaceutical Group Limited By Share's (SZSE:002864) Shareholders Will Receive A Bigger Dividend Than Last Year

We Think That There Are Some Issues For Shaanxi Panlong Pharmaceutical Group Limited By Share (SZSE:002864) Beyond Its Promising Earnings

May 02
We Think That There Are Some Issues For Shaanxi Panlong Pharmaceutical Group Limited By Share (SZSE:002864) Beyond Its Promising Earnings

Earnings Not Telling The Story For Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SZSE:002864) After Shares Rise 32%

Mar 06
Earnings Not Telling The Story For Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SZSE:002864) After Shares Rise 32%

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Shaanxi Panlong Pharmaceutical Group Limited By Share 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

SZSE:002864 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CNY Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
9/30/202498211677150N/A
6/30/202493611679156N/A
3/31/202496512096166N/A
12/31/202398111042104N/A
9/30/20239971074393N/A
6/30/20231,04311166113N/A
3/31/20231,0011033387N/A
1/1/202397410170125N/A
9/30/20229589877149N/A
6/30/20229179673151N/A
3/31/20229119668151N/A
1/1/20228879335116N/A
9/30/20218428646136N/A
6/30/20218348928114N/A
3/31/202176487-276N/A
12/31/2020670792192N/A
9/30/202062680572N/A
6/30/202056566-152N/A
3/31/2020571703879N/A
12/31/2019611723468N/A
9/30/2019587763557N/A
6/30/2019564724161N/A
3/31/2019516673353N/A
12/31/2018489652747N/A
9/30/2018442572236N/A
6/30/201842456N/A22N/A
3/31/201840446N/A30N/A
12/31/201737744N/A28N/A
9/30/201736949N/A41N/A
6/30/201733344N/A62N/A
3/31/201730540N/A52N/A
12/31/201630540N/A62N/A
12/31/201525643N/A41N/A
12/31/201424640N/A49N/A
12/31/201322733N/A25N/A

애널리스트 미래 성장 예측

수입 대 저축률: Insufficient data to determine if 002864's forecast earnings growth is above the savings rate (2.9%).

수익 vs 시장: Insufficient data to determine if 002864's earnings are forecast to grow faster than the CN market

고성장 수익: Insufficient data to determine if 002864's earnings are expected to grow significantly over the next 3 years.

수익 대 시장: Insufficient data to determine if 002864's revenue is forecast to grow faster than the CN market.

고성장 수익: Insufficient data to determine if 002864's revenue is forecast to grow faster than 20% per year.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: Insufficient data to determine if 002864's Return on Equity is forecast to be high in 3 years time


성장 기업 발견